Can alpha-immunotherapy succeed where other systemic modalities have failed?
Allen
B J
BJ
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000922:Immunotoxins; D009362:Neoplasm Metastasis / Q000517:prevention & control*
D000970:Antineoplastic Agents; D000922:Immunotoxins